July 20, 2016 12:32 AM EDT
R&D

Syn­thorx lines up some big syn­thet­ic bi­ol­o­gy R&D goals af­ter grab­bing a $10M round

John Carroll

Editor & Founder

Syn­thet­ic bi­ol­o­gy of­fers some dra­mat­ic pos­si­bil­i­ties in the drug de­vel­op­ment world. And now one of the up­start pi­o­neers in the field of syn­thet­ic life has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times